LVRS

Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment

Retrieved on: 
Friday, August 20, 2021
Medical Devices, Insurance, Hospitals, Clinical Trials, Professional Services, Other Health, Biotechnology, Managed Care, General Health, Health, SEC, COPD, Securities Act of 1933, Safety, Endobronchial valve, Lung, Atmosphere, GOLD, Securities Exchange Act of 1934, University, U.S. Securities and Exchange Commission, Policy, Health Care Service Corporation, Â, Breathe Me, Blues, Degenerative disease, Respiratory disease, Quality of life, Drug Quality and Security Act, Adoption, BCBS, Valve, NASDAQ, Chronic obstructive pulmonary disease, FDA, Security (finance), Oxygen, Corporation, LVRS, Global Initiative, Interventional pulmonology, Bronchoscopy, Han Lifei (d. 1424), Patient, Medical imaging, the Zephyr Valve Treatment, Pulmonx Corporation, THE ZEPHYR VALVE TREATMENT, PULMONX CORPORATION

Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonxs Zephyr Valve, for severe emphysema, a form of COPD.

Key Points: 
  • Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonxs Zephyr Valve, for severe emphysema, a form of COPD.
  • This follows similar coverage decisions by other BCBS plans and brings the total BCBS covered members in the US to 59 million.
  • Not surprisingly, the policy cites our published data, which demonstrate the safety, effectiveness and long-term positive patient outcomes of our Zephyr valve treatment."
  • The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema, a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue.